BA
NVCR icon

Bridgewater Associates’s NovoCure NVCR Stock Holding History

Bridgewater Associates’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,119
Closed -$331K – 757
2024
Q4 		$331K Sell
11,119
-28,264
-72% -$598K ﹤0.01% 619
2024
Q3 		$616K Sell
39,383
-41,898
-52% -$760K ﹤0.01% 668
2024
Q2 		$1.39M Sell
81,281
-16,181
-17% -$285K 0.01% 605
2024
Q1 		$1.52M Buy
97,462
+11,286
+13% +$166K 0.01% 532
2023
Q4 		$1.29M Buy
86,176
+59,048
+218% +$790K 0.01% 601
2023
Q3 		$438K Sell
27,128
-88,098
-76% -$2.54M ﹤0.01% 700
2023
Q2 		$4.78M Sell
115,226
-12,518
-10% -$777K 0.03% 317
2023
Q1 		$7.68M Sell
127,744
-7,999
-6% -$639K 0.05% 243
2022
Q4 		$9.96M Sell
135,743
-30,759
-18% -$2.31M 0.05% 251
2022
Q3 		$12.7M Buy
166,502
+15,032
+10% +$1.17M 0.06% 215
2022
Q2 		$10.5M Buy
151,470
+15,190
+11% +$1.14M 0.04% 315
2022
Q1 		$11.3M Buy
136,280
+36,879
+37% +$2.72M 0.05% 278
2021
Q4 		$7.46M Buy
99,401
+3,295
+3% +$331K 0.04% 228
2021
Q3 		$11.2M Sell
96,106
-536
-0.6% -$81K 0.06% 188
2021
Q2 		$21.4M Buy
+96,642
New +$18.8M 0.14% 123

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bridgewater Associates's NVCR Position: Q1 2025 in Review

Bridgewater Associates sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 11,119 shares — an estimated $331K sold.

Bridgewater Associates first reported a position in NVCR in Q2 2021 and held it in 15 quarters. The position peaked at $21.4M in Q2 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Bridgewater Associates reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • Bridgewater Associates sold 11,119 NovoCure shares in Q1 2025, an estimated $331K.
  • Bridgewater Associates first reported a position in NovoCure in Q2 2021 and held it in 15 quarters.
  • Bridgewater Associates's NovoCure position peaked at $21.4M in Q2 2021.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Bridgewater Associates's 13F filing for Q1 2025, filed 14 May 2025.